Distinguished in Medullary Thyroid Carcinoma

Qinghai Ji

Department Of Head And Neck Surgery, 
Shanghai, CN 
Distinguished in Medullary Thyroid Carcinoma
Department Of Head And Neck Surgery, 
Shanghai, CN 
OverviewLocationsClinical Research

Overview

Qinghai Ji practices in Shanghai, China. Ji is rated as a Distinguished expert by MediFind in the treatment of Medullary Thyroid Carcinoma. Their top areas of expertise are Papillary Thyroid Cancer, Thyroid Cancer, Medullary Thyroid Carcinoma, Thyroidectomy, and Laryngectomy.

Their clinical research consists of co-authoring 89 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 9 articles and participated in 2 clinical trials in the study of Medullary Thyroid Carcinoma.

Locations

Department Of Head And Neck Surgery, Shanghai, China
Other Locations
Department Of Head And Neck Tumor, Tianjin, China
Zhongshan, 200032, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
A Phase 2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
A Multi-center , Opened, Phase II Study of Safety and Efficacy of Sulfatinib in Advanced Medullary Thyroid Carcinoma ( MTC) and Iodine-refractory Differentiated Thyroid Carcinoma (DTC)
A Multi-center , Opened, Phase II Study of Safety and Efficacy of Sulfatinib in Advanced Medullary Thyroid Carcinoma ( MTC) and Iodine-refractory Differentiated Thyroid Carcinoma (DTC)
Enrollment Status: Completed
Publish Date: February 13, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

89 Total Publications

Updated Thresholds of Basal Calcitonin Level and Extent of Lymph Node Metastasis in Initially Treated Medullary Thyroid Cancer.
Updated Thresholds of Basal Calcitonin Level and Extent of Lymph Node Metastasis in Initially Treated Medullary Thyroid Cancer.
Journal: JAMA otolaryngology-- head & neck surgery
Published: June 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ji's expertise for a condition
ConditionClose
View All 12 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile